title: Proliferation hemangiomas formation through dual mechanism of vascular endothelial growth factor mediated endothelial progenitor cells proliferation and mobilization through matrix metalloproteinases 9.
abstract: Infantile hemangioma is the most common tumor of infancy and the mechanism leading to proliferation hemangiomas formation is poorly understood and currently no successful treatment modality exists. We hypothesize that EPCs formed during proliferation hemangiomas, as the result of vascular endothelial growth factor (VEGF) stimulation through MMP9, play the major role in the control of cell proliferation and capillary-like vessels production. Accepting the hypothesis to be correct, a therapy that inhibits EPC mobilization and proliferation can be used to prevent the proliferation hemangiomas formation. Current therapies are only partially effective and safe because they could not eliminate all the relative factors of proliferation hemangiomas formation at all, such as: EPCs in the peripheral blood, and at the same time inducing death (apoptosis and necrosis) of other normal cells. A more efficient prevention of proliferation hemangiomas could be achieved using specific drugs or biologic methods that inhibit EPC mobilization and proliferation. Therapy based on gene therapy, capable to specifically inhibit VEGF and MMP9 expression in gene level, can be possibly effective.
authors: Department of Burn and Plastic Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.
authors: Guo-You
authors: GY
authors: Zhang
authors: Cheng-Gang
authors: CG
authors: Yi
authors: Xuan
authors: X
authors: Li
authors: Zi-Qian
authors: ZQ
authors: Liang
authors: Run-Xiu
authors: RX
authors: Wang
authors: Da-En
authors: DE
authors: Liu
authors: Li-Ming
authors: LM
authors: Zhang
authors: Cheng-Yue
authors: CY
authors: Meng
authors: Shu-Zhong
authors: SZ
authors: Guo
mesh_terms: D002196:Capillaries / Q000378:metabolism; D049109:Cell Proliferation; D042783:Endothelial Cells / Q000166:cytology*; D005434:Flow Cytometry / Q000379:methods; D015316:Genetic Therapy / Q000379:methods; D006391:Hemangioma / Q000209:etiology* / Q000473:pathology*; D006801:Humans; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D008954:Models, Biological; D008962:Models, Theoretical; D018919:Neovascularization, Physiologic; D013234:Stem Cells / Q000166:cytology*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*
chemical_list: D042461:Vascular Endothelial Growth Factor A; D020780:Matrix Metalloproteinase 9